University of Hertfordshire

Role of prostacyclin in pulmonary hypertension

Research output: Contribution to journalArticlepeer-review

Standard

Role of prostacyclin in pulmonary hypertension. / Mitchell, Jane A.; Ahmetaj-Shala, Blerina ; Kirkby, Nick; Wright, William R.; MacKenzie, Louise Susan; Reed, Dan; Mohamed, Nura.

In: Global Cardiology Science and Practice, Vol. 2014, No. 4, 53, 31.12.2014.

Research output: Contribution to journalArticlepeer-review

Harvard

Mitchell, JA, Ahmetaj-Shala, B, Kirkby, N, Wright, WR, MacKenzie, LS, Reed, D & Mohamed, N 2014, 'Role of prostacyclin in pulmonary hypertension', Global Cardiology Science and Practice, vol. 2014, no. 4, 53. https://doi.org/10.5339/gcsp.2014.53

APA

Mitchell, J. A., Ahmetaj-Shala, B., Kirkby, N., Wright, W. R., MacKenzie, L. S., Reed, D., & Mohamed, N. (2014). Role of prostacyclin in pulmonary hypertension. Global Cardiology Science and Practice, 2014(4), [53]. https://doi.org/10.5339/gcsp.2014.53

Vancouver

Mitchell JA, Ahmetaj-Shala B, Kirkby N, Wright WR, MacKenzie LS, Reed D et al. Role of prostacyclin in pulmonary hypertension. Global Cardiology Science and Practice. 2014 Dec 31;2014(4). 53. https://doi.org/10.5339/gcsp.2014.53

Author

Mitchell, Jane A. ; Ahmetaj-Shala, Blerina ; Kirkby, Nick ; Wright, William R. ; MacKenzie, Louise Susan ; Reed, Dan ; Mohamed, Nura. / Role of prostacyclin in pulmonary hypertension. In: Global Cardiology Science and Practice. 2014 ; Vol. 2014, No. 4.

Bibtex

@article{543f506a00bc4494a3c9bd1e3ed4ce1f,
title = "Role of prostacyclin in pulmonary hypertension",
abstract = "Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it{\textquoteright}s discovery in the 1980s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension",
author = "Mitchell, {Jane A.} and Blerina Ahmetaj-Shala and Nick Kirkby and Wright, {William R.} and MacKenzie, {Louise Susan} and Dan Reed and Nura Mohamed",
note = "Date of Acceptance: 11/12/2014 This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.",
year = "2014",
month = dec,
day = "31",
doi = "10.5339/gcsp.2014.53",
language = "English",
volume = "2014",
journal = "Global Cardiology Science and Practice",
issn = "2305-7823",
publisher = "Bloomsbury Qatar Foundation Journals",
number = "4",

}

RIS

TY - JOUR

T1 - Role of prostacyclin in pulmonary hypertension

AU - Mitchell, Jane A.

AU - Ahmetaj-Shala, Blerina

AU - Kirkby, Nick

AU - Wright, William R.

AU - MacKenzie, Louise Susan

AU - Reed, Dan

AU - Mohamed, Nura

N1 - Date of Acceptance: 11/12/2014 This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

PY - 2014/12/31

Y1 - 2014/12/31

N2 - Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it’s discovery in the 1980s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension

AB - Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it’s discovery in the 1980s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension

U2 - 10.5339/gcsp.2014.53

DO - 10.5339/gcsp.2014.53

M3 - Article

VL - 2014

JO - Global Cardiology Science and Practice

JF - Global Cardiology Science and Practice

SN - 2305-7823

IS - 4

M1 - 53

ER -